Testing for myeloid and lymphoid malignancies needs to be fast
Successful treatment and improved prognosis of hematological cancer is directly impacted by the speed and efficacy of diagnosis.1
The complexity of hematological malignancies often means laboratories have to use an interrogative and iterative testing approach across multiple different platforms. Leveraging Cell3 Target NGS panels to detect all key variants allows laboratories to streamline their workflows into one single test advancing hemato-oncology patient care.
The Cell3 Target: PanHemeOnc panel, designed by WMRGL is available as a customer-led design for any lab also looking to streamline their lymphoid and myeloid workflows.
"Clearly, the most efficient approach [for myeloid and lymphoid testing] is to have, as far as possible, everything going down one streamlined pathway.”
A targeted NGS panel, that can detect SNVs, indels and CNVs in genes associated with both myeloid and lymphoid has huge advantages for Jo Masons team in West Midlands Regional Genomics Laboratory (WMRGL) in the reduction of turnaround times and cost burdens associated with multi-testing approaches.
Profile all key myeloid and lymphoid mutations in one test
The panel design covers variants in 134 genes (including SRY for gender ID only) and 13 key regions for CNVs*, as well as boosted FLT3 coverage, KMT2A including exons and introns 1-14, and whole gene deletion events†
* CNV coverage: CNV del(1p), CNV gain(1q), CNV (11q), CNV 13q14; del(17p), CNV del(17p), CN-LOH 6p, CEBPA, GATA2, RUNX1, TERC, TERT, trisomy12
† Whole gene deletion events: CEBPA, GATA2, RUNX1, TERC, TERT
Complete coverage of key genes
All transcripts covered for all genes
